Serum C3 Levels Are Diagnostically More Sensitive and Specific for Systemic Lupus Erythematosus Activity Than Are Serum C4 Levels

Ricker, Denise M.; Hebert, Lee A.; Rohde, Richard D.; Sedmak, Daniel D.; Lewis, Edmund J.; Clough, John D.

doi:10.1016/s0272-6386(12)80609-3

Cited by 48 publications

(20 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, C3 is more sensitive and speci®c for lupus nephritis activity than are serum C4 levels. 15,16 Renal biopsy pathology Change in the NIH-modi®ed, semiquantitative renal pathology scoring system, especially in chronicity (damage) index, is considered a clinically relevant outcome for lupus nephritis but its use requires training and a dedicated pathology service. 17,18 It has been argued that in the non-academic practice setting, this system may be less reproducible, 19 but the majority of investigators have found the system highly reproducible with experience.…”

Section: Proteinuriamentioning

confidence: 99%

Outcome criteria for lupus nephritis trials: A critical overview

Boumpas¹,

Balow

1998

Lupus

View full text Add to dashboard Cite

Lupus nephritis is an important cause of morbidity and mortality in patients with systemic lupus erythematosus. Traditional outcome criteria such as doubling of serum creatinine, end-stage renal disease and death have been used in controlled therapeutic trials, but are limited by their low incidence and the extended period of time required to reach them. More recently, discussions have focused on composite outcome measures, such as remission and relapse, as well as measures of health-related quality of life, general lupus activity and cumulative damage indexes. We review the strengths and weaknesses of several outcome criteria, and we propose criteria for both small pilot studies and large definitive trials.

show abstract

Section: Proteinuriamentioning

confidence: 99%

Outcome criteria for lupus nephritis trials: A critical overview

Boumpas¹,

Balow

1998

Lupus

View full text Add to dashboard Cite

show abstract

“…98 severe disease in SLE, including renal flares. [74][75][76] In recent l ongitudinal studies, baseline reductions in complement C3 or C4 were shown to predict disease flares two months or even a year before they occurred. 67 77 Finally, the utility of reduced complement in predicting and monitoring treatment response has also been validated in recent clinical trials aimed at depleting B cells using rituximab or blocking the BAFF pathway.…”

Section: Systemic Sclerosismentioning

confidence: 99%

Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Mohan

Assassi

2015

BMJ

View full text Add to dashboard Cite

Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting--for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis and polymyositis, and axial spondyloarthritis (including ankylosing spondylitis). It will discuss how these markers can facilitate early diagnosis as well as more accurate subclassification and assessment of disease activity in the clinical setting. The ultimate goal of current and future biomarkers in rheumatic diseases is to enable early detection of these diseases and their clinical manifestations, and to provide effective monitoring and treatment regimens that are tailored to each patient's needs and prognosis.

show abstract

“…The European league against rheumatism has proposed some useful recommendations for monitoring patients with SLE in clinical practice and observational studies [3]. Traditionally the presence of anti-double stranded DNA (anti-dsDNA) and hypo-complement in serum have been used to diagnose SLE, and their quantitative changes have been further used to reflect the disease activity [4,5]. However, some researchers found them less useful [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

The Important Roles of C4d in Systemic Lupus Erythematosus

Li¹

2014

Rheumatol Curr Res

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of various autoantibodies and the injury of multiple systems. It is well known that the complement system plays an important role in the pathogenesis of SLE. Complement activation product C4d is a marker of the classical complement activation and hence can be used to reflect the tissue injury as well as therapeutic effects. Besides its important role in antibody-mediated rejection, C4d has been increasingly recognized as a potential biomarker in SLE. Here we will summarize the recent advances of C4d in SLE.

show abstract

Serum C3 Levels Are Diagnostically More Sensitive and Specific for Systemic Lupus Erythematosus Activity Than Are Serum C4 Levels

Cited by 48 publications

References 10 publications

Outcome criteria for lupus nephritis trials: A critical overview

Outcome criteria for lupus nephritis trials: A critical overview

Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

The Important Roles of C4d in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About